AccurKardia
AccurKardia leverages AI to interpret ECG signals, transforming them into a powerful diagnostic biomarker to improve health outcomes and save lives. The company develops FDA-cleared and investigational AI-driven ECG interpretation solutions, including AccurECG™, AK-AVS™, and AK+ Guard™, aimed at advancing cardiac diagnostics and monitoring.
Industries
Nr. of Employees
small (1-50)
Patents
Machine learning algorithm for the detection of cardiac amyloidosis from 12 lead ECG data
US-12620488-B2
View Details
Machine learning algorithm for the detection of cardiac amyloidosis from 12 lead ECG data
US-12620488-B2
View DetailsProducts
FDA-cleared ECG analysis system (510(k) cleared)
A device-agnostic ECG analysis platform cleared via FDA 510(k) that performs beat-level analysis, rhythm classification, ectopic beat detection, and generates annotated ECG summaries for clinical use.
Investigational ECG screening models (research-use only)
Research-stage AI models for screening conditions from ECG data, including aortic valve stenosis screening from 12-lead ECGs and hyperkalemia detection from single-lead ECGs; these models are described as investigational, not cleared for clinical diagnosis, and have patent filings pending.
FDA-cleared ECG analysis system (510(k) cleared)
A device-agnostic ECG analysis platform cleared via FDA 510(k) that performs beat-level analysis, rhythm classification, ectopic beat detection, and generates annotated ECG summaries for clinical use.
Investigational ECG screening models (research-use only)
Research-stage AI models for screening conditions from ECG data, including aortic valve stenosis screening from 12-lead ECGs and hyperkalemia detection from single-lead ECGs; these models are described as investigational, not cleared for clinical diagnosis, and have patent filings pending.
Services
Provision of programmatic endpoints and web interfaces that accept ECG data and return annotated analysis and diagnostic outputs for integration into clinical systems.
Collaboration with independent researchers and institutions to evaluate investigational AI models for ECG-based screening applications and to provide access to white papers and validation data.
Provision of programmatic endpoints and web interfaces that accept ECG data and return annotated analysis and diagnostic outputs for integration into clinical systems.
Collaboration with independent researchers and institutions to evaluate investigational AI models for ECG-based screening applications and to provide access to white papers and validation data.
Expertise Areas
- ECG analytics and AI-driven diagnostics
- Clinical signal processing for short- and long-duration ECGs
- Remote patient monitoring and ambulatory ECG workflow integration
- Algorithm validation and clinical research for ECG-based biomarkers
Key Technologies
- AI / machine learning for ECG analysis
- 12-lead ECG signal processing
- Single-lead (lead I) ECG analysis
- Continuous and long-duration ECG data processing
News & Updates
AccurKardia is using AI to mine the information contained in widely available 12-lead ECG data. The startup's mission is to ...
AccurKardia, an innovator in ECG-based diagnostics technology, today announced that its AccurECGTM software platform has ...
HeartBeam Inc., a medical technology company focused on transforming cardiac care by providing powerful personalized insights, ...
AK+ Guard is artificial intelligence–powered software that uses lead I ECG data to alert patients and clinicians of moderate to ...
AccurKardia's AK+ Guard is designed to work with a wide range of FDA-cleared consumer and clinical wearables that currently ...
AccurKardia has received FDA Breakthrough Device Designation for its AI-driven ECG-based Aortic Valve Stenosis screening ...
AccurKardia is using AI to mine the information contained in widely available 12-lead ECG data. The startup's mission is to ...
AccurKardia, an innovator in ECG-based diagnostics technology, today announced that its AccurECGTM software platform has ...
HeartBeam Inc., a medical technology company focused on transforming cardiac care by providing powerful personalized insights, ...
AK+ Guard is artificial intelligence–powered software that uses lead I ECG data to alert patients and clinicians of moderate to ...
AccurKardia's AK+ Guard is designed to work with a wide range of FDA-cleared consumer and clinical wearables that currently ...
AccurKardia has received FDA Breakthrough Device Designation for its AI-driven ECG-based Aortic Valve Stenosis screening ...